- Pfizer’s quit-smoking drug not linked to depression or heart risks (reuters.com)
Pfizer's stop-smoking drug Chantix (varenicline) does not raise risks of heart attack or depression, contrary to previous reports, and should be recommended to more smokers wanting to quit, scientists said…researchers found that patients who took Chantix,..marketed as Champix in Europe, were no more likely to suffer a heart attack than those using nicotine replacement therapy or another quit-smoking drug…also not at higher risk of depression or self-harm...
- International pharmaceutical groups involved in large corruption scandal in Romania (romania-insider.com)
National Anticorruption Directorate …investigation on deals between Romanian doctors and drug companies for cancer drug prescriptions might target 11 of the largest pharmaceutical companies in the local market…. anticorruption prosecutors….targeting... arrangements between doctors and pharma companies.
- Roche
- Actavis
- Pfizer
- Teva
- Novartis
- Alvogen
- Sandoz
- Glaxosmithkline
- Egis
- Romastru Trading
- Glenmark
- China slaps Pfizer with $500,000 in Viagra penalties for pharmacy tie-up (fiercepharma.com)
Pfizer has no problem keeping sales for Viagra flying high in China,… But the company has gotten in hot water for its efforts, as Chinese marketing authorities slapped Pfizer with a fine for paying local drugstores to promote its blockbuster ED med. Pfizer inked deals with four Shanghai pharmacies to display the drug… violating China's drug management rules...
- Pfizer’s revenue, profit beat as vaccine sales rise (newsdaily.com)
Pfizer….reported better-than-expected second-quarter profit and revenue, helped by strong demand for its pneumonia vaccine (Prevnar ) and new breast cancer drug (Ibrance), sending its shares up 1 percent…. global vaccines unit rose 44 percent to $1.58 billion… breast cancer drug ...generated $140 million in sales in its first full quarter on the market..
- Britain raps Pfizer over huge jump in epilepsy drug price (newsdaily.com)
Britain’s competition watchdog has accused Pfizer and Flynn Pharma of breaching UK and European law by ramping up the cost of an epilepsy drug,..by as much as 2,600 percent…Competition and Markets Authority said …each abused a dominant position by charging "excessive and unfair" prices for phenytoin sodium capsules.